千红制药发布可转债发行审核问询函回复及更新公告，投资者需关注进展与风险
2026年5月26日，常州千红生化制药股份有限公司（证券代码：002550，证券简称：千红制药）发布了关于向不特定对象发行可转换公司债券的审核问询函回复及募集说明书等申请文件更新的提示性公告。
公告主要内容及关键点：
- 深交所受理本次可转债发行申请： 公司于2026年1月23日收到深圳证券交易所（深交所）出具的受理通知，确认向不特定对象发行可转债的申请文件齐备并予以受理。
- 收到审核问询函并逐项回复： 2026年2月12日，公司收到深交所上市审核机构出具的审核问询函。公司与发行相关中介机构对问询函所列问题进行了认真逐项落实与回复。
- 募集说明书及相关文件同步更新： 鉴于公司已于2026年4月24日披露《2025年年度报告》，公司联合中介机构对募集说明书等相关申请文件中的财务数据及其他变动事项进行了同步更新，并在巨潮资讯网公开披露。
- 发行尚需通过多重审批： 本次可转债发行事项尚需通过深交所审核，并获得中国证券监督管理委员会注册批准后方可实施。能否通过审核及最终注册、以及时间节点均存在不确定性。
- 提醒投资者注意风险： 公司承诺将根据事项进展及时履行信息披露义务，提醒广大投资者关注投资风险。
- 信息披露保证声明： 公司及董事会全体成员承诺本次信息披露真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。
投资者需要重点关注与潜在影响：
- 可转债发行进展：可转债发行能否通过深交所审核及证监会注册决定，直接影响公司融资能力、资本结构及未来发展战略。该事项的不确定性可能导致股价波动。
- 财务数据与公司经营状况：募集说明书等文件已根据最新年度报告同步更新，投资者应关注公司财务及经营最新情况对可转债发行及公司估值的影响。
- 监管风险：若审核未通过或注册受阻，公司融资计划将受影响，可能对股价产生负面影响。
- 信息披露进度：公司承诺及时披露后续进展，投资者应密切关注后续公告。
结论
本次公告涉及公司重大融资事项，尚处于审核阶段，能否顺利实施及相关审批进展具备较强的不确定性，对公司未来发展和股价存在潜在影响，属于重要且价格敏感信息。
免责声明：本文仅为信息披露解读，不构成投资建议。投资者应结合自身情况谨慎决策，关注公司后续公告及相关风险。
Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Releases Key Update on Convertible Bond Issuance – Investors Should Closely Monitor Progress and Risks
On May 26, 2026, Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. (Stock Code: 002550, Stock Name: Qianhong Pharmaceutical) issued a significant announcement regarding its response to the Shenzhen Stock Exchange’s review inquiry letter and the update of application documents, including the prospectus for its proposed convertible bond offering to non-specific investors.
Main Content and Key Points:
- SZSE Accepts Convertible Bond Application: On January 23, 2026, the company received a notice from the Shenzhen Stock Exchange confirming that the application documents for the convertible bond issuance were complete and officially accepted.
- Inquiry Letter and Thorough Response: On February 12, 2026, Qianhong Pharmaceutical received a review inquiry letter from the SZSE. The company, together with its intermediaries, carefully addressed each issue raised in the inquiry.
- Prospectus and Related Documents Updated: Following the disclosure of its 2025 annual report on April 24, 2026, the company, together with intermediaries, updated financial and other relevant data in the application documents, with the updated files disclosed via CNINFO.
- Issuance Requires Multiple Approvals: The convertible bond issuance still requires SZSE review and approval, as well as registration with the China Securities Regulatory Commission. The outcome and timing remain uncertain.
- Investor Risk Warning: The company has pledged to promptly disclose information as the process advances and reminds investors to be aware of investment risks.
- Information Disclosure Assurance: The company and all board members guarantee the truthfulness, accuracy, and completeness of the disclosed information, with no false, misleading statements, or major omissions.
Key Considerations and Potential Impact for Investors:
- Progress of Convertible Bond Issuance: The success or failure of the issuance, subject to regulatory approval, will directly impact Qianhong’s financing capability, capital structure, and strategic development. The uncertainty could lead to share price volatility.
- Updated Financials and Company Performance: The prospectus and application documents have been updated to reflect the latest annual report. Investors should assess how current financials and operations may affect the bond issuance and company valuation.
- Regulatory Risks: If approval is not granted or registration is delayed, the financing plan could be jeopardized, with possible negative effects on share price.
- Disclosure Progress: The company has committed to timely updates. Investors should closely follow subsequent announcements.
Conclusion
This announcement pertains to a major financing initiative, still under regulatory review. The outcome and timing are highly uncertain, potentially impacting the company’s future development and share price. It is an important, price-sensitive disclosure.
Disclaimer: This article is for information interpretation only and does not constitute investment advice. Investors should make prudent decisions based on their own circumstances and pay attention to subsequent company announcements and risks.
